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Abstract
Introduction: The use of the drug infliximab for the treatment of patients with Crohn’s disease can
be complicated by tuberculosis. A paradoxical reaction during antituberculosis chemotherapy and
immunologic reconstitution after discontinuation of infliximab can result in severe disseminated
tuberculosis.
Case presentation: A 38-year-old Korean man with severe Crohn’s disease presented with fever
and diffuse abdominal pain. Infliximab had been started 2 months before admission. A chest X-ray and
abdominal computed tomography scan revealed numerous miliary nodules in both lung fields and
microabscesses in the spleen. Given the diagnosis of disseminated tuberculosis, the infliximab therapy
was discontinued and antituberculosis therapy was promptly started. Over the next 3 months, the
patient was diagnosed with tuberculosis lymphadenitis on a right supraclavicular lymph node and
surgical excision of the lesion was performed. With the diagnosis of a paradoxical response, anti-
tuberculous therapy was continued for 12 months.
Conclusion: Our case suggests that patients who develop tuberculosis after infliximab exposure are
at an increased risk of developing a paradoxical reaction. The current recommendation of
discontinuing infliximab during tuberculosis treatment should be re-evaluated.
Introduction
In 1998, the drug infliximab, developed from a murine-
human chimeric anti-tumor necrosis factor (TNF) mono-
clonal antibody that binds diverse TNF moieties, was
approved by the US Food and Drug Administration for the
treatment of Crohn’s disease [1]. However, infliximab
poses a risk for reactivation of latent granulomatous
infections by disrupting established granulomas; this
occurs due to the neutralization of soluble TNF that is
essential for the formation and maintenance of a
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physical barriers to mycobacterial dissemination in
patients with latent tuberculous infections.
A paradoxical deterioration during anti-tubercular therapy
is defined as a transient worsening of disease, at a pre-
existing site, or the development of new tuberculous
lesions in a patient who initially improved on anti-
tubercular therapy. This phenomenon is more commonly
associated with extrapulmonary tuberculosis [3]. A para-
doxical exacerbation of the signs and symptoms of
tuberculosis may occur not only after tubercular therapy,
but also after discontinuation of TNF-a inhibitors during
the treatment of active tuberculosis, due to an enhanced
antituberculous immune response.
Although there is ample data suggesting an association
between treatment with infliximab and the development
of tuberculosis, there has been some debate on the
treatment of paradoxical reactions and disseminated
tuberculosis in patients treated with infliximab [4–6].
Here, we describe a patient who became systemically ill
with disseminated Mycobacterium tuberculosis infection,
and had a paradoxical response to discontinuation of
TNF-a inhibitors during anti-tuberculous therapy.
Case presentation
The patient was a 38-year-old Korean man with severe
Crohn’s disease that had beendiagnosedby clinical features
and colonoscopy findings 9 years previously. The patient
had been hospitalized with a 2 week history of fever and
diffuse abdominal pain. He had been started on infliximab
(Remicade®, Centocor) which had been given at baseline
and at 2 and 6 weeks. Infliximab infusion therapy was
performed three times because of an aggravated Crohn’s
disease activity index and unresponsiveness to high-dose
steroids (methylprednisolone 60mg). The tuberculin skin
test was negative, and chest X-rays were normal before the
infliximab administration. Three weeks later, the patient
started to complain of fever, diffuse abdominal discomfort
and fatigue. On admission, his temperature was 39 degrees
Celsius, pulse rate 100/min, respiratory rate 24/min and
blood pressure 100/80mmHg. Routine physical examina-
tion did not show any physical abnormalities except for
diffuse abdominal tenderness without rebound tenderness.
Laboratory investigations revealed anemia (Hct 31.1%, Hb
9.89g/dL), an elevated C-reactive protein level (9.1mg/L),
an elevated erythrocyte sedimentation rate (90mm/h) and
no other abnormal findings. Chest X-ray and abdominal
computed tomography (CT) scan (Figure 1a), performed
shortly after admission, revealed numerous miliary nodules
in both lung fields and multiple tiny low density nodular
lesions in the spleen that were consistent with micro-
abscesses (Figure 1b and 1c). The tuberculin skin test on
admission was positive (16mm). Induced sputum was
obtainedandacid-fastbacilli(AFB)stainingandculturesfor
Mycobacterium tuberculosis were positive.
Histologic examination of a lung-tissue sample obtained
by percutaneous needle biopsy showed a chronic caseating
granulomatous inflammation. In addition, AFB staining of
lung tissue revealed acid-fast bacilli. Polymerase chain
reaction confirmed an infection with M. tuberculosis. The
tuberculosis culture confirmed M. tuberculosis which was
susceptible to all anti-tuberculous drugs. Infliximab
therapy was discontinued, and antituberculosis therapy
(isoniazid, rifampin, pyrazinamide and ethambutol) was
promptly started after confirmation of the diagnosis. After
2 days of therapy, the fever resolved and then the other
symptoms progressively improved.
Over the next 3 months, the patient was compliant with
the antituberculous medication. However, he presented
with a painful swelling of a right supraclavicular lymph
node with redness and warmth at the site of the lesion. We
performed a CT scan of the cervical region and thorax that
showed poorly enhanced lesions in the right upper
Figure 1.
Chest X-ray and computerized tomography scans of
the abdomen and neck. (a) Chest X-ray revealed
numerous miliary nodules in both lungs sparing the
costophrenic angles. (b) There were numerous miliary
nodules in the left lower lung field. (c) An abdominal
computerized tomography scan shows multiple tiny
low-density nodular lesions in the spleen. (d) Computerized
tomography of the neck shows poorly enhanced lesions in the
right upper paratracheal region related to the tuberculosis
lymphadenitis.
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region and left supraclavicular fossa consistent with
tuberculosis lymphadenitis (Figure 1d). Surgical excision
of the supraclavicular lymph node was performed due to
complaints of pain and purulent discharge from a fistula.
Histologic examination of the lymph node samples
revealed chronic caseating granulomatous inflammation,
but the AFB staining and culture were negative. The
diagnosis of a paradoxical response was made; isoniazid,
rifampin and ethambutol were continued without change
of the treatment regimen. The patient completed a
12-month course because miliary nodules and splenic
microabscess were still noted on a follow-up CT scan. His
Crohn’s disease was controlled with mesalazine, after
remission had been achieved with the three cycles of
inflixmab.
Discussion
Paradoxical worsening during therapy for tuberculosis is a
well-recognized phenomenon. A paradoxical reaction, or
immune reconstitution, occurs more commonly in patients
infected with human immunodeficiency virus (HIV), who
aresimultaneouslytreated with antiretroviral therapy [7]. In
this case, the newly developed supraclavicular tuberculous
lymphadenitis may have represented a similar immune
reconstitution after recovery from iatrogenic immunosup-
pression. The patient was treated with surgical resection of
the lesion without modification of the antituberculous
regimenbecauseofcomplaintsofpainandfistulaformation.
Paradoxical response does not warrant more drugs or
longer medication. Many studies have shown that utilising
rifampin, isoniazid, pyrazinamide and ethambutol for the
initial phase, followed by rifampin and isoniazid for a
further continuation phase, should be the recommended
standard treatment for adult pulmonary or extra-pulmon-
ary tuberculosis. It is now well established that ethambu-
tol can be omitted in patients with a low risk of resistance
to isoniazid according to the recommendations by the
World Health Organization [8]. But the Korean Academy
of Tuberculosis and Respiratory Disease (1997) and the
Korean Centers of Disease Control and Prevention (2005)
recommend the ethambutol combination for patients
with drug susceptible tuberculosis, because the resistance
rate to isoniazid is more than 4% in Korea. The new
guidelines of the Korean Academy of Tuberculosis and
Respiratory Disease (2005) argue that a regimen of
rifampin and isoniazid in continuation phases is sufficient
for patients with drug-susceptible tuberculosis. Hence the
need for ethambutol in the continuation phase of
chemotherapy can still be optional in cases in Korea.
Our patient received three doses of infliximab after
negative findings of both tuberculin skin test screening
and chest X-ray screening. However, before the screening
tuberculin skin test, the patient received a high dose of
steroid treatment, which might have affected the result of
thetuberculin skin test.A falsenegative tuberculin skin test
has been previously reported during immunosuppression
with prednisone, azathioprine and infliximab [6]. TNF-a,
an inflammatory cytokine expressed by activated macro-
phages, T-cells and other immune cells, plays a crucial role
in host responses against tuberculosis, including granu-
loma formation and inhibition of dissemination [9]. Thus,
patients with tuberculosis who lack adequate TNF-a
production are at risk for disseminated, rapidly progres-
sing and unusual presentations of tuberculosis. Infliximab
is a chimeric antibody against TNF-a, resulting in the loss
of the ability by macrophages to sequester mycobacteria
through phagocytosis, as well as failure of induction of
mycobacterial eradication [9]. Although the clinical
efficacy of infliximab is well established, there are many
case reports and studies showing an increased risk of
tuberculosis in patients treated with infliximab [4,10].
Paradoxical reactions generally occur within 1 to 3 months
of initiation of treatment. Several theories of pathogenesis
have been proposed for paradoxical tuberculous reactions,
yettheprecisemechanismsremaintobedefined.Onetheory
to explain paradoxical responses is an excessive inflamma-
tory response in the context of immune reconstitution and
increased antigen exposure after tuberculosis therapy [11].
Whyparadoxicalreactionstodrugtherapyshouldoccuronly
insomeindividualsisunclear;however,itislikelytobedue
to a complex interplay of the host immune responses,
tubercle bacilli virulence, antigen load, the site of infection
and the effects of the chemotherapy. Paradoxical reactions
with tuberculosis have been well studied in patients with
HIV infections.Themassive deliveryofmembraneantigens,
after the initiation of antituberculosis treatment, has been
advocated as the cause of paradoxical responses in immu-
nocompetent patients [12]. However, in HIV-infected
patients, immunologic restoration after antiretroviral ther-
apy, andrecovery of specific responsestocertain antigens, is
another possible mechanism [11].
In our case, an increased antigen exposure after tuberculosis
chemotherapy, and immunologic reconstitution secondary
tothediscontinuationofinfliximab,mightbeimplicatedin
the development of a paradoxical reaction, similar to
patients infected with HIV. The current recommendation
is for the discontinuation of TNF-a inhibitors in patients
during treatment for active tuberculosis; this is mandatory
for those patients with proven mycobacterial infections
[12,13]. However, there is no contra-indication to systemic
glucocorticoid therapy in patients with tuberculosis being
treated with infliximab [13]. Glucocorticoid therapy is
recommended in patients with tuberculous meningitis or
pericarditis. The outcomes with other immunosuppressive
agents during the treatment of tuberculosis have been
Page 3 of 4
(page number not for citation purposes)
Journal of Medical Case Reports 2009, 3:6673 http://jmedicalcasereports.com/jmedicalcasereports/article/view/3/4/6673variable. Studies on tuberculosis in organ transplant
recipients suggest that that chances of survival are not
decreasedbytheuseofcyclosporineorazathioprine[14].In
addition,reportsonthetreatmentoftuberculosisassociated
with HIV have shown that highly immunosuppressed
patients respond well to standard tuberculosis therapy;
some clinicians recommend withholding the initiation of
antiretroviral therapy until the completion of the intensive
phase of tuberculosis treatment [15]. Other reports suggest,
however,themaintenanceoflowdosesofaTNF-ainhibitor
ortocontinuetheTNF-ainhibitortherapyduringtreatment
of active tuberculosis; at present, the safety implications of
either approach are unclear [4–6,13]. However, this
approach to treatment should be considered because the
immunologic regulation could provide control of Crohn’s
disease and be beneficial in these patients.
Conclusion
Our case suggests that patients who develop tuberculosis
after infliximab exposure are at increased risk of a
paradoxical reaction. Therefore, the current recommenda-
tion for the discontinuation of TNF-a inhibitors in
patients with Crohn’s disease during the treatment of
active tuberculosis should be re-evaluated. Additional
studies are required to evaluate the safety and efficacy of
continuing TNF-a inhibitors during tuberculosis therapy.
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